As these new treatments become available, we want to make sure that they are delivered through the NHS to people with type 1 diabetes as quickly as possible.
To achieve this we provide evidence and patient input to the National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN). These are the two organisations that evaluate which medicines should be prescribed and paid for by the NHS, and provide guidelines to doctors about best treatment practices.
As well as providing input for NICE and SIGN treatment reviews ourselves, we work with industry and researchers to ensure that they are producing appropriate evidence for these two bodies. We also make sure that patients’ views are represented by asking people with type 1 diabetes to take part in reviews, and we help to keep people with type 1 up to date about the best and latest treatment options so that they can discuss them with their healthcare team.
We are a member of the Medical Technology Group (MTG), a coalition of patient groups, research charities and medical device manufacturers working to improve access to cost-effective medical technologies for everyone who needs them.
In 2018 we merged with diabetes technology advocacy group Input to address some of the problems which delay adoption of new treatments and technology through the NHS. We also work closely with partners like Diabetes UK, and we worked with Input and Diabetes UK to produce a family-friendly type 1 tech guide to NICE guidance on technology for children and young people with diabetes. You can download it by going to our information packs and leaflet page.
Some of our work
Read our Position Statements.
We submitted evidence to the Select Committee for Health and Social Care’s enquiry into the NHS White Paper. We advocated for greater involvement of people with type 1 in choosing their treatment and healthcare, and supported the opportunities to address and remove health inequalities. Read our full evidence submission.
We responded to NICE’s Health Technology Evaluation consultation. Using our findings from Pathway to Choice, we promoted more consistent access to type 1 diabetes technology and accelerating innovative treatments.
Pathway to Choice
Pathway to Choice is a partnership programme led by JDRF and supported by industry partners Abbott Diabetes Care, Dexcom, Insulet International Ltd and Roche Diabetes Care.
The aim of the programme is to build awareness of and access to type 1 technology choices for people with type 1 diabetes. It does this through building insight to influence health decision-makers, increasing understanding of technologies among people with type 1 diabetes and raising public awareness of type 1 diabetes and its treatment.
The findings of our Pathway to Choice report, launched in February 2020, will enable us to explore the types of support and interventions we can develop to help people living with type 1 diabetes choose the best possible treatments.